Look­ing to win over some skep­ti­cal an­a­lysts, Rhythm beats the drum on in­ter­im da­ta in PhII bas­ket study for ad­di­tion­al in­di­ca­tions

Rhythm Phar­ma­ceu­ti­cals has been work­ing to­ward ex­pand­ing the FDA ap­proval they re­ceived just two months ago for three rare ge­net­ic dis­or­ders that re­sult in obe­si­ty. In De­cem­ber, their Phase III cut of da­ta saw mixed re­ac­tions from an­a­lysts, but new in­ter­im re­sults re­leased Tues­day may pro­vide more ex­cite­ment.

In an on­go­ing Phase II study for set­melan­otide across in­di­vid­u­als with one of three dis­tinct rare ge­net­ic dis­eases of obe­si­ty, 65 pa­tients had reached the Dec. 17 cut­off date for eval­u­a­tion. Among pa­tients who met the pri­ma­ry end­point of at least 5% weight loss over three months, Rhythm saw an av­er­age re­duc­tion of no less than 7.1% in any of the groups.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER